Loading organizations...
Loading organizations...

AAVantgarde Bio: Clinical-stage biotech developing AAV gene therapies using split-AAV technology for inherited retinal diseases.
AAVantgarde Bio is a clinical-stage biotechnology company developing adeno-associated viral vector gene therapies for inherited retinal diseases, based in Milan and Naples, Italy. The enterprise utilizes proprietary split-AAV technology to deliver large genes that exceed standard packaging capacities, addressing the genetic root causes of conditions like Stargardt disease and Usher syndrome type 1B. The company has secured significant capital to advance its clinical pipeline, including a $141 million Series B round and a prior €61 million Series A financing in 2023. AAVantgarde Bio is backed by a syndicate of institutional investors, including Amgen Ventures, Forbion, Longwood Fund, and Sofinnova Partners. These funds support the progression of its lead clinical programs, AAVB-039 and AAVB-081, through early-stage human trials. The company was spun out from the Telethon Institute of Genetics and Medicine and founded in 2021 by Alberto Auricchio.
AAVantgarde Bio has raised $205.0M across 2 funding rounds.
AAVantgarde Bio has raised $205.0M in total across 2 funding rounds.
AAVantgarde Bio has raised $205.0M in total across 2 funding rounds.
AAVantgarde Bio's investors include Harry Raikes, Atlas Venture, Max Klement, Forbion, Longwood Fund, Roche Venture Fund, Soffinova Partners, Westlake Village BioPartners, Amgen Ventures, Athos Capital, CDP Venture Capital, Neva SGR.
AAVantgarde Bio is a clinical‑stage biotechnology company developing proprietary AAV (adeno‑associated virus) vector platforms that enable delivery of large genes for gene therapies, initially focused on inherited retinal disorders such as Usher Syndrome type 1B and Stargardt disease[1][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Medical Landscape
Quick Take & Future Outlook
If you’d like, I can: produce a timeline of AAVantgarde’s milestones, summarize the scientific mechanisms (dual‑hybrid recombination vs. intein splicing) in lay terms, or list recent clinical updates and investor/partner activity with source citations.
AAVantgarde Bio has raised $205.0M across 2 funding rounds. Most recently, it raised $140.0M Series B in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $140.0M Series B | Harry Raikes | Atlas Venture, Max Klement, Forbion, Longwood Fund, Roche Venture Fund, Soffinova Partners, Westlake Village BioPartners, Amgen Ventures, Athos Capital, CDP Venture Capital, Neva SGR, Sixty Degree Capital, Willett Advisors, XGen Ventures |
| Jun 1, 2023 | $65.0M Series A | Atlas Venture, Forbion, Jason Gardner | Max Klement, Longwood Fund, Roche Venture Fund, Soffinova Partners, Westlake Village BioPartners, David Steinberg |